The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases

Abstract

Introduction: With the safety of human papilloma virus vaccine (HPVv) being questioned, this article aims to assess the risks and benefits of the commercially available HPVv. Within the last decade, two vaccines (Gardasil and Cervarix) have been put on the market to prevent infection with the most oncogenic HPV subtypes. Both vaccines contain aluminum adjuvants that are meant to cause a hyper stimulated immune response to prevent HPV infection.

Areas covered: The purpose of this paper is to consider the safety of these two vaccines based on the data from the U.S. Vaccine Adverse Event Reporting System (VAERS) and case reports.

Expert opinion: The current HPVv are both effective and generally safe. However, it should be noted that autoimmune side effects have been reported in several studies. Further research should be done to understand the relationship between HPVv and autoimmunity.

Keywords:

• adjuvant
• aluminum
• autoimmune/inflammatory syndrome induced by adjuvants
• autoimmunity
• guillain barré syndrome
• human papilloma virus
• postural orthostatic tachycardia syndrome
• premature ovarian failure
• vaccines

Declaration of interest

Y Shoenfeld has served as an expert witness in cases involving adverse vaccine reaction in the no-fault US National Vaccone Injury Compensation Program. L Tomljenovic received fundng from Luther Allyn Shourds Dean estate Foundation (Private foundation). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes

This box summarizes key points contained in the article.